|
Real-time Estimate
Cboe BZX
09:39:18 11/03/2026 pm IST
|
5-day change
|
1st Jan Change
|
|
129.44 USD
|
-0.32%
|
 |
-3.20%
|
-8.92%
|
|
11/03 |
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
|
PR
| |
09/03 |
Neurocrine Biosciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08:40 AM
| | |
04/03 |
Neurocrine Biosciences, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:50 AM
| | |
25/02 |
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
|
PR
| |
13/02 |
UBS Adjusts Price Target on Neurocrine Biosciences to $161 From $178, Maintains Buy Rating
|
MT
| |
12/02 |
Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says
|
MT
| |
12/02 |
Wedbush Adjusts Neurocrine Biosciences Price Target to $151 From $149, Maintains Outperform Rating
|
MT
| |
12/02 |
RBC Trims Price Target on Neurocrine Biosciences to $177 From $180, Keeps Outperform Rating
|
MT
| |
12/02 |
Morgan Stanley Trims Price Target on Neurocrine Biosciences to $173 From $175, Keeps Equalweight Rating
|
MT
| |
12/02 |
Neurocrine Biosciences : Presentation (Final NBIX Q4 and FY 2025 Earnings Presentation 02 WT5vGfd16)
|
PU
| |
12/02 |
Neurocrine Biosciences, Inc., Q4 2025 Earnings Call, Feb 11, 2026
| | |
12/02 |
Neurocrine Biosciences : Presentation (Final NBIX Q4 and FY 2025 Earnings Presentation 0216)
|
PU
| |
12/02 |
Neurocrine Biosciences Fiscal Q4 Adjusted Earnings, Revenue Rise; Sets INGREZZA FY Guidance
|
MT
| |
12/02 |
Neurocrine: Q4 Earnings Snapshot
|
AQ
| |
12/02 |
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M
|
MT
| |
12/02 |
Tranche Update on Neurocrine Biosciences, Inc.'s Equity Buyback Plan announced on February 21, 2025.
|
CI
| |
12/02 |
Neurocrine Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
|
CI
| |
12/02 |
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M
|
MT
| |
12/02 |
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q4 Adjusted EPS $1.88 per Share, vs. FactSet Est of $1.80
|
MT
| |
12/02 |
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
|
PR
| |
12/02 |
Neurocrine Biosciences, Inc. Provides Product Sales Guidance for the Fiscal Year 2026
|
CI
| |
26/01 |
Neurocrine Biosciences, Inc. Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
|
CI
| |
26/01 |
Neurocrine Biosciences Starts Phase 2 Study for Tardive Dyskinesia Treatment
|
MT
| |
26/01 |
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
|
PR
| |
23/01 |
UBS Adjusts Price Target on Neurocrine Biosciences to $178 From $188, Maintains Buy Rating
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
